English (UK)
中文版Privity FZ LLE 
Privity was founded in 2004, an independent Venture-focused advisory firm that seeks entrepreneurs with interesting and unique ideas and helps them develop and grow. Privity is agnostic to geography and industry vertical. It focuses on the quality of the entrepreneur and the compelling value proposition of the idea.
Mr. Sleem Hasan
Founder & CEO
Rancho Santa Fe Bio,Inc. 
We licensed the drug from the Mayo Clinic and the drug has been part of the NIH's NCAT's Program in which they put in $5 million for our Phase I and Phase II clinical trials and Sanofi put in another $1 million for manufacturing.
We are raising a Series A round now and we welcome interest from Chinese investors and partners.
You can reach me at 858-205-5091.
Thanks.
----Randy Berholtz
Mr. Randy Berholtz
Chairman and CEO
Regulaxis 
Regulaxis SAS is a French biotech company created in 2013 to develop innovative therapies for human clinic based on new synthetic peptides regulating cell growth and differentiation.
Regulaxis is specialized in the regulation of cell proliferation and/or cell differentiation. The potential therapeutic applications covered by our patents are very broad, especially in the areas of joint/bone or nerve cell regeneration, but also in cancer and related metabolic diseases (diabetes, obesity …).
Our mission is to grant licenses of innovative molecules in a pharmaceutical company after completion of phase II clinical proof of concept.
Regulaxis is strategically focused only on high unmet medical needs but has elected as its first priority:
regeneration of articular cartilage using intra-articular injections of its lead candidate REG-O3.
Dr. Matthieu CHAREYRE
Chief Business Development Officer - Global Pharmaceutical Operations
Regulaxis SAS
Regulaxis SAS is a French biotech company created in 2013 to develop innovative therapies for human clinic based on new synthetic peptides regulating cell growth and differentiation.
Regulaxis is specialized in the regulation of cell proliferation and/or cell differentiation. The potential therapeutic applications covered by our patents are very broad, especially in the areas of joint/bone or nerve cell regeneration, but also in cancer and related metabolic diseases (diabetes, obesity …).
Our mission is to grant licenses of innovative molecules in a pharmaceutical company after completion of phase II clinical proof of concept.
Regulaxis is strategically focused only on high unmet medical needs but has elected as its first priority:
regeneration of articular cartilage using intra-articular injections of its lead candidate REG-O3.
Mr. Raffaello Paolini
R&D Project Manager – East Asian operations developmentRespinova Ltd. 
Respinova’s Pulsehaler™ technology is the first and only treatment to directly re-open the collapsed small airways of COPD patients, thereby reducing breathlessness and improving patient’s ability to walk. The technology was clinically proven in a clinical study, and published in the peer reviewed Journal of COPD. Our technology is protected by 6 patent families, with 15 issued patents and many additional pending patents.
Respinova’s technology pipeline also includes devices for improving delivery of inhaled drugs. This technology was clinically proven to deliver drugs more than 200% better than traditional nebulizers, with significant improvements in lung function. We have begun initial discussions with Pharma companies to partner in the development of Best-in-Class inhaled therapies, including COPD, Cystic Fibrosis, Asthma, Idiopathic Pulmonary Fibrosis, and Pulmonary Arterial Hypertension.
Cliff Ansel
CEORius Medical UG (Haftungsbeschränkt) 
Mr. Denis Demarais
Founder and CEOSelfit Medical
The company has developed a therapist robot based on AI and neuroscience with focus on physical and cognitive health.
Responsive Web Design powered by 